VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+25.81%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$241M
AUM Growth
+$50.3M
(+26%)
Cap. Flow
+$11.6M
Cap. Flow
% of AUM
4.82%
Top 10 Holdings %
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17
Top Buys
| 1 |
Brookfield Renewable
BEPC
|
$1.83M |
| 2 |
Western Midstream Partners
WES
|
$1.11M |
| 3 |
Delek US
DK
|
$829K |
| 4 |
Viper Energy
VNOM
|
$789K |
| 5 |
Oneok
OKE
|
$751K |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$1.61M |
| 2 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$1.13M |
| 3 |
AIV
Aimco
AIV
|
$1.11M |
| 4 |
Telefônica Brasil
VIV
|
$1.01M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$988K |
Sector Composition
| 1 | Healthcare | 29.53% |
| 2 | Real Estate | 18.96% |
| 3 | Energy | 16.61% |
| 4 | Materials | 11.31% |
| 5 | Utilities | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MTEM
276
DELISTED
Molecular Templates, Inc.
MTEM
| $270K | 0.11% |
1,915
+463
| +32% | +$65.3K |
|
|
ALBO
277
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $270K | 0.11% |
+7,192
| New | +$270K |
|
278
Applied Therapeutics
APLT
$68.2M
| $269K | 0.11% |
12,216
+4,645
| +61% | +$102K |
|
279
Ascendis Pharma
ASND
$12.5B
| $269K | 0.11% |
1,614
-601
| -27% | -$100K |
|
280
MEI Pharma
MEIP
$139M
| $269K | 0.11% |
5,095
+679
| +15% | +$35.8K |
|
281
Revolution Medicines
RVMD
$7.57B
| $269K | 0.11% |
6,805
-1,733
| -20% | -$68.5K |
|
|
PRVB
282
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $269K | 0.11% |
15,878
-5,607
| -26% | -$95K |
|
|
SRNE
283
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $269K | 0.11% |
39,387
-27,464
| -41% | -$188K |
|
|
CNST
284
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $269K | 0.11% |
9,331
+391
| +4% | +$11.3K |
|
285
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $268K | 0.11% |
15,148
+831
| +6% | +$14.7K |
|
|
TCDA
286
DELISTED
Tricida, Inc. Common Stock
TCDA
| $267K | 0.11% |
37,919
+25,838
| +214% | +$182K |
|
287
Allogene Therapeutics
ALLO
$255M
| $266K | 0.11% |
10,536
+2,925
| +38% | +$73.8K |
|
288
Akero Therapeutics
AKRO
$3.58B
| $265K | 0.11% |
10,276
-2,410
| -19% | -$62.2K |
|
|
EFR
289
Eaton Vance Senior Floating-Rate Fund
EFR
$343M
| $265K | 0.11% |
20,802
-4,644
| -18% | -$59.2K |
|
290
Keros Therapeutics
KROS
$633M
| $265K | 0.11% |
+3,758
| New | +$265K |
|
|
ATNX
291
DELISTED
Athenex, Inc. Common Stock
ATNX
| $265K | 0.11% |
1,200
-55
| -4% | -$12.1K |
|
292
AnaptysBio
ANAB
$613M
| $263K | 0.11% |
12,251
-4,381
| -26% | -$94.1K |
|
|
DRNA
293
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $263K | 0.11% |
11,939
-3,425
| -22% | -$75.4K |
|
|
IMGN
294
DELISTED
Immunogen Inc
IMGN
| $262K | 0.11% |
40,635
-29,578
| -42% | -$191K |
|
295
Cardiff Oncology
CRDF
$144M
| $261K | 0.11% |
+14,533
| New | +$261K |
|
296
Nkarta
NKTX
$161M
| $261K | 0.11% |
+4,239
| New | +$261K |
|
297
NextCure
NXTC
$13M
| $261K | 0.11% |
1,999
+917
| +85% | +$120K |
|
298
Akebia Therapeutics
AKBA
$785M
| $260K | 0.11% |
92,771
+65,225
| +237% | +$183K |
|
299
BioCryst Pharmaceuticals
BCRX
$1.74B
| $259K | 0.11% |
34,707
-37,137
| -52% | -$277K |
|
300
Syndax Pharmaceuticals
SNDX
$1.47B
| $259K | 0.11% |
11,624
-8,270
| -42% | -$184K |
|